Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials.

@article{Stone2001NormalF,
  title={Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials.},
  author={Gregg Whitney Stone and David Alan Cox and Eulogio Garc{\'i}a and Bruce R. Brodie and Marie Claude Morice and Jeffrey D. Griffin and Luiz Alberto Piva e Mattos and Alexandra J Lansky and William W O'neill and Cindy Lee Grines},
  journal={Circulation},
  year={2001},
  volume={104 6},
  pages={636-41}
}
BACKGROUND Whereas survival after lytic therapy for myocardial infarction is strongly dependent on early administration, it is unknown whether the otherwise excellent outcomes in patients undergoing primary PTCA for acute myocardial infarction, in whom TIMI-3 flow rates of >90% may be achieved, can be further improved by early reperfusion. METHODS AND RESULTS Among 2507 patients enrolled in 4 PAMI trials undergoing primary PTCA, spontaneous reperfusion (TIMI-3 flow) was present in 16% at… CONTINUE READING
146 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 146 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial.Circulation

  • EM Antman, RP Giugliano, CM Gibson
  • 1999

Similar Papers

Loading similar papers…